Guggenheim Forecasts Strong Price Appreciation for Nautilus Biotechnology (NASDAQ:NAUT) Stock

Nautilus Biotechnology (NASDAQ:NAUT) had its price target increased by equities research analysts at Guggenheim from $2.50 to $4.00 in a research note issued to investors on Friday,Benzinga reports. The brokerage currently has a “buy” rating on the stock. Guggenheim’s price target points to a potential upside of 65.29% from the company’s previous close.

A number of other analysts also recently issued reports on the company. Wall Street Zen raised Nautilus Biotechnology from a “sell” rating to a “hold” rating in a research report on Tuesday, November 18th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Nautilus Biotechnology in a research report on Thursday, January 22nd. One research analyst has rated the stock with a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Hold” and a consensus target price of $4.00.

Nautilus Biotechnology Price Performance

NASDAQ NAUT opened at $2.42 on Friday. The firm’s 50 day moving average is $2.16 and its 200-day moving average is $1.58. The company has a market capitalization of $305.67 million, a PE ratio of -5.15 and a beta of 1.49. Nautilus Biotechnology has a 12-month low of $0.62 and a 12-month high of $3.08.

Nautilus Biotechnology (NASDAQ:NAUT) last announced its earnings results on Thursday, February 26th. The company reported ($0.11) EPS for the quarter, topping the consensus estimate of ($0.14) by $0.03. As a group, sell-side analysts expect that Nautilus Biotechnology will post -0.57 EPS for the current year.

Institutional Trading of Nautilus Biotechnology

A number of hedge funds have recently modified their holdings of the stock. Sentinel Trust Co. LBA bought a new stake in shares of Nautilus Biotechnology during the 4th quarter worth about $1,462,000. Corient Private Wealth LLC raised its holdings in Nautilus Biotechnology by 860.0% in the 2nd quarter. Corient Private Wealth LLC now owns 435,350 shares of the company’s stock valued at $316,000 after acquiring an additional 390,000 shares during the period. Jacobs Levy Equity Management Inc. acquired a new stake in Nautilus Biotechnology during the first quarter worth approximately $194,000. Y Intercept Hong Kong Ltd bought a new stake in shares of Nautilus Biotechnology during the second quarter worth approximately $163,000. Finally, Jane Street Group LLC increased its stake in shares of Nautilus Biotechnology by 304.1% during the second quarter. Jane Street Group LLC now owns 290,369 shares of the company’s stock worth $210,000 after purchasing an additional 218,512 shares during the period. Institutional investors and hedge funds own 50.71% of the company’s stock.

Key Stories Impacting Nautilus Biotechnology

Here are the key news stories impacting Nautilus Biotechnology this week:

• Positive Sentiment: Guggenheim raised its price target to $4.00 from $2.50 and initiated/maintained a “buy” rating, implying ~65% upside from the recent price — this analyst action likely supported buying interest. Guggenheim price-target raise
• Positive Sentiment: Q4 2025 results beat expectations on the bottom line: Nautilus reported EPS of ($0.11) vs. consensus ($0.14), and management highlighted strategic progress on its platform and early-access customers — the beat and commentary support a constructive near-term outlook. Earnings release and call
• Neutral Sentiment: Management’s earnings call and published transcripts emphasized “strategic advances” and commercial progress (early-access program ramp), which are positive developments but still early-stage—impact depends on successful scale-up and conversion to sustained revenue. Earnings call transcript
• Negative Sentiment: Nautilus guided to 15%–20% expense growth in 2026 as it scales the early-access program — higher operating spend will widen losses near-term and raises execution risk if commercialization or customer uptake lags expectations. Expense guidance article

About Nautilus Biotechnology

Nautilus Biotechnology is a life sciences company developing a next-generation proteomics platform that aims to provide high-resolution, single-molecule protein analysis. Its core technology combines proprietary microfluidics, advanced optics and custom reagents to capture and identify thousands of proteins simultaneously, offering researchers detailed insights into cellular processes and disease biology. The company’s platform is designed to improve sensitivity, reproducibility and throughput compared with traditional mass spectrometry approaches.

Founded in 2016 and headquartered in Seattle, Washington, Nautilus Biotechnology serves pharmaceutical and biotechnology companies, academic institutions and research organizations seeking to accelerate drug discovery and biomarker research.